Selexis SA and SpyBiotech have signed a commercial license agreement (CLA) to advance SPYVLP102, SpyBiotech’s lead vaccine program for human cytomegalovirus (HCMV)
JSR Life Sciences that the JSR Corporation has finalized the acquisition of all outstanding shares in MBL. As a result, MBL is a wholly owned subsidiary and affiliate of the JSR Life Sciences famil...
BITT will leverage Selexis’ suite of proprietary modular technologies designed to overcome the complex challenges of protein-expression and deliver the high performance research cell banks necessar...
Acquisition augments CrownBio’s preclinical in vitro service platforms, adding high content imaging and advanced tumor organoid analytics to three-dimensional immuno-oncology drug assays
“Quality downstream applications are key to maximizing the full potential of in vivo study results, including our wealth of historical model and treatment data,”
